Continuum Advisory LLC Raises Stock Position in Stryker Corporation $SYK

Key Points

• Continuum Advisory increased its Stryker position by 413.1% in the second quarter, bringing its holdings to 7,937 shares valued at approximately $2.5 million. Institutional investors and hedge funds collectively own 77.09% of the company.
• Stryker exceeded quarterly earnings expectations with EPS of $3.69 and revenue of $6.59 billion, up 9.4% year over year. The company reaffirmed fiscal 2026 EPS guidance of $14.95–$15.10 and declared a quarterly dividend of $0.88.
• Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and a $386.28 price target, although recent insider sales and the stock’s elevated valuation remain potential concerns.

Continuum Advisory LLC lifted its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 413.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,937 shares of the medical technology company's stock after acquiring an additional 6,390 shares during the quarter. Continuum Advisory LLC's holdings in Stryker were worth $2,499,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in SYK. Norges Bank purchased a new stake in shares of Stryker in the fourth quarter worth about $1,822,272,000. Bank of America Corp DE purchased a new stake in shares of Stryker during the 2nd quarter valued at about $1,404,284,000. Auto Owners Insurance Co raised its holdings in shares of Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock valued at $1,024,444,000 after buying an additional 2,906,448 shares during the period. Legal & General Group Plc acquired a new position in Stryker during the 2nd quarter worth approximately $707,212,000. Finally, Jupiter Topco LLC acquired a new position in Stryker during the 2nd quarter worth approximately $681,581,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of NYSE SYK opened at $312.10 on Thursday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The business has a 50 day moving average price of $329.60 and a two-hundred day moving average price of $330.33. The firm has a market cap of $119.71 billion, a PE ratio of 32.34, a price-to-earnings-growth ratio of 1.99 and a beta of 0.76.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker's quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker's dividend payout ratio is currently 36.48%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Truist Financial increased their price objective on shares of Stryker from $330.00 to $340.00 and gave the company a "hold" rating in a research report on Friday, July 31st. BTIG Research reduced their target price on shares of Stryker from $371.00 to $358.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. Wolfe Research downgraded shares of Stryker from an "outperform" rating to a "peer perform" rating in a research note on Thursday, August 13th. Citigroup reaffirmed a "buy" rating on shares of Stryker in a report on Thursday, August 13th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $386.28.

Insider Activity at Stryker

In other Stryker news, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 50,000 shares of the firm's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares of the company's stock, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock valued at $118,197,701 over the last ninety days. Corporate insiders own 4.60% of the company's stock.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Director Mary Brainerd purchased additional Stryker shares on September 2, increasing her personal stake. Insider buying can signal confidence in the company’s valuation and outlook, although the purchase alone is unlikely to materially change earnings expectations. Stryker Insider Makes Bold New Move With Fresh Share Purchase
• Positive Sentiment: Stryker received FDA De Novo authorization for SportSuite Vision, its surgical application for Apple Vision Pro, and completed the first reported hip arthroscopy using the system. The technology could strengthen Stryker’s digital-surgery and orthopedic innovation offerings, though commercial adoption remains to be demonstrated. Stryker introduces FDA-authorized surgical application for Apple Vision Pro
• Positive Sentiment: Stryker agreed to acquire ZuriMED, adding the FiberLocker System and expanding its shoulder-care and rotator-cuff portfolio. The deal could broaden Stryker’s orthopedic product lineup and growth opportunities. Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
• Neutral Sentiment: Analysts remain broadly optimistic about Stryker’s longer-term prospects even as the shares have underperformed the broader market. The company’s latest reported quarter exceeded earnings expectations, but its valuation remains relatively elevated, which can increase sensitivity to growth concerns. Is Stryker Stock Underperforming the Nasdaq?
• Negative Sentiment: The recent underperformance suggests investors may be focused more on valuation, execution, and market-wide factors than on the new product announcements. The ZuriMED transaction also introduces integration and spending risks, with financial terms and its near-term earnings contribution not specified in the available reports.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source